Xyosted
Antares/Halozyme, subcutaneous testosterone auto-injector
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- FDA Approved (Xyosted 2018)
Reference only. Not medical advice.
What can go wrong
Blood-pressure elevation (boxed/warning). Higher cost than generic cypionate vials. Injection-site reactions.
This is something to take to a clinician. The Atlas can tell you what is known about xyosted in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Xyosted (testosterone enanthate; Antares Pharma, FDA-approved 2018) is a once-weekly subcutaneous auto-injector that delivers a small fixed dose with a hidden needle. Its appeal is stable levels (weekly subQ avoids biweekly swings) and ease of self-administration without drawing from a vial. The FDA approval came with a warning about blood-pressure elevation, requiring monitoring. It is a branded, more expensive alternative to drawing generic cypionate.
Testosterone enanthate in a once-weekly subcutaneous pen.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
Safety in detail
Carries an FDA warning for blood-pressure increase; monitor BP. Physician oversight required.
What it does to fertility
Suppresses spermatogenesis; not fertility-preserving.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total testosterone
- Hematocrit
- Blood pressure
- PSA (over 40)
What people get wrong
Often saidXyosted is just expensive cypionate
ActuallyIt is enanthate in a fixed-dose subQ pen; the value is convenience and stable subQ levels, but it is materially pricier than vial-and-syringe generic testosterone.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Active
- Testosterone enanthate
- Route
- SubQ auto-injector, once weekly
- Approved
- 2018
- Warning
- Blood-pressure increase
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Xyosted. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.